{"id":"W7093303736","doi":"10.1210/jendso/bvaf149.2237","title":"OR31-04 Efficacy and Safety of Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Topline Results","year":2025,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Ophthalmology and Eye Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Placebo; Adverse effect; Clinical endpoint; Antagonist; Phases of clinical research; Monoclonal antibody; Receptor antagonist; Antagonism","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004545739,0.0002382242,0.0006236223,0.0001187931,0.0001547061,0.00001197848,0.0002626934,0.00008176098,0.00004688486],"category_scores_gemma":[0.0008085485,0.0001662423,0.0004074558,0.0005254302,0.0002522021,0.0001165842,0.0002056697,0.0007322138,0.000002744446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001460065,"about_ca_system_score_gemma":0.0003993521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003646207,"about_ca_topic_score_gemma":0.000004430487,"domain_scores_codex":[0.9981333,0.0001373434,0.0008214047,0.0002710245,0.0003057523,0.0003311971],"domain_scores_gemma":[0.9984604,0.0002822173,0.0004122592,0.000346601,0.0002727275,0.0002258375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3237701,0.02040714,0.2319298,0.001257585,0.004943604,0.001498375,0.01469873,0.001800628,0.2962846,0.0007426349,0.08459195,0.01807488],"study_design_scores_gemma":[0.1064396,0.005041864,0.8304635,0.002532391,0.001277724,0.0004150587,0.00642001,0.0005571766,0.02090887,0.000962603,0.0243359,0.0006452721],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9753385,0.001254125,0.0000625071,0.021574,0.0003897299,0.000560643,0.0001544858,0.000009748609,0.0006562799],"genre_scores_gemma":[0.9962685,0.0009779339,0.0007933519,0.0008256017,0.0001712396,0.000005309621,0.00003981421,0.00001684169,0.00090142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5985337,"threshold_uncertainty_score":0.6779163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009867363082910592,"score_gpt":0.348483179231671,"score_spread":0.3386158161487604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}